PROKIDNEY CORP.
PROKIDNEY CORP. (PROK): 5 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
10.2 months
D/E -0.03
Lead: Phase 3
5 candidates
1 upcoming, next in ~1262d
N/A
A transparent, data-derived signal for PROKIDNEY CORP.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$505.3M
Cash
$101.9M
Quarterly Burn
$41.7M
Runway
10.2 mo
Revenue
$226K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| react | Phase 3 |
| react/gen | Preclinical |
| react/universal | Preclinical |
| renal autologous cell therapy | Phase 2 |
| rilparencel | Phase 1 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
67
Total value held
$69.2M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 12,341,266 | $22.1M |
| morgan stanley | 8,955,967 | $16.0M |
| vanguard capital management llc | 2,293,874 | $4.1M |
| millennium management llc | 2,271,577 | $4.1M |
| blackrock, inc. | 1,387,116 | $2.5M |
| renaissance technologies llc | 1,250,794 | $2.2M |
| geode capital management, llc | 1,230,409 | $2.2M |
| marshall wace, llp | 1,011,744 | $1.8M |
| woodline partners lp | 1,000,000 | $1.8M |
| bank of america corp /de/ | 753,412 | $1.3M |
Showing top 10 of 67 institutional holders of PROKIDNEY CORP.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PROKIDNEY CORP.'s pipeline?
PROKIDNEY CORP. (PROK) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PROKIDNEY CORP.'s lead drug candidate?
PROKIDNEY CORP.'s most advanced tracked candidate is react (Phase 3) for CKD due to congenital anomalies of the kidney and urinary tract (CAKUT).
What is PROKIDNEY CORP.'s next catalyst?
PROKIDNEY CORP.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type" — expected December 1, 2029.
What is PROKIDNEY CORP.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PROKIDNEY CORP. has approximately 10.2 months of cash runway.
What is PROKIDNEY CORP.'s market capitalization?
PROKIDNEY CORP.'s market capitalization is approximately $505.3M.
Get the full picture on PROKIDNEY CORP.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.